Control of parafunction with bite plane therapy

Pilot study of the effect of altered vertical dimension bite plane therapy on myofascial pain dysfunction and temporomandibular joint dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26019919

Enrollment

Registered

2017-11-02

Start date

2000-01-01

Completion date

Unknown

Last updated

2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TMD, MPD, Sleep Stages Not Applicable TMD, MPD, Sleep Stages

Interventions

Patients are examined clinically, complete clinical histories, have impressions taken for fabrication of mandibular Gelb bite planes, and have lateral cephalograms and panoramic radiographs taken. Pa

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Permanent dentitions with no more than 1 tooth missing per quadrant (excluding wisdom teeth) 2. No implants or partial dentures 3. Not undergoing current treatment for TMD/MPD 3. Females aged 20-57

Exclusion criteria

Exclusion criteria: 1. Male 2. Children and seniors 3. Multiple missing teeth in each quadrant 4. Dental implants 5. Partial dentures 6. Active treatment for TAD/MPD

Design outcomes

Primary

Measure	Time frame
1. TMD symptoms are measured using the TMJ scale at baseline and study end 2. Bruxism is measured using the polysomnograph at baseline and study end 3. Daytime sleepiness is measured using Epworth Sleepiness Scale at baseline and study end 4. Pain symptoms with treatment is measured using the McGill pain questionnaire at baseline and study end 5. Patient symptoms are measured using the Helkimo Index at baseline and study end	—

Measure

Time frame

1. TMD symptoms are measured using the TMJ scale at baseline and study end 2. Bruxism is measured using the polysomnograph at baseline and study end 3. Daytime sleepiness is measured using Epworth Sleepiness Scale at baseline and study end 4. Pain symptoms with treatment is measured using the McGill pain questionnaire at baseline and study end 5. Patient symptoms are measured using the Helkimo Index at baseline and study end

—

Secondary

Measure	Time frame
There are no secondary outcome measures.	—

Countries

Canada

Contacts

Public ContactDouglas Awde

doug@adpcorp.ca+1 519 672 5456

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026